

# Sutureless versus Conventional Aortic Valve Replacement:

## Outcomes in 70 High-Risk Patients Undergoing Concomitant Cardiac Procedures

Muhammet Onur Hanedan,  
MD  
Mehmet Ali Yuruk, MD  
Ali Ihsan Parlar, MD  
Ugur Ziyrek, MD  
Ali Kemal Arslan, MD  
Ufuk Sayar, MD  
Ilker Mataraci, MD

*In elderly, high-risk surgical patients, sutureless aortic valve replacement (AVR) can often be an alternative to conventional AVR; shorter aortic cross-clamp and cardiopulmonary bypass times are the chief advantages. We compared the outcomes of sutureless AVR with those of conventional AVR in 70 elderly patients who underwent concomitant cardiac surgical procedures.*

*We retrospectively analyzed the cases of 42 men and 28 women (mean age, 70.4 ± 10.3 yr; range, 34–93 yr) who underwent cardiac operations plus AVR with either a sutureless valve (group 1, n=38) or a conventional bioprosthetic or mechanical valve (group 2, n=32). Baseline patient characteristics were similar except for worse New York Heart Association functional status and the prevalence of diabetes mellitus in group 1.*

*In group 1, the operative, cross-clamp, and cardiopulmonary bypass times were shorter (all P=0.001), postoperative drainage amounts were lower (P=0.009), hospital stays were shorter (P=0.004), and less red blood cell transfusion was needed (P=0.037). Echocardiograms before patients' discharge from the hospital showed lower peak and mean aortic gradients in group 1 (mean transvalvular gradient, 8.4 ± 2.8 vs 12.2 ± 5.2 mmHg; P=0.012).*

*We found that elderly, high-risk patients who underwent multiple cardiac surgical procedures and sutureless AVR had better hemodynamic outcomes and shorter ischemic times than did patients who underwent conventional AVR. (Tex Heart Inst J 2018;45(1):11-6)*

**Key words:** Aged; aortic valve insufficiency/surgery/therapy; heart valve prosthesis implantation/adverse effects/instrumentation/methods/mortality; hemodynamics; prospective studies; prosthesis design; risk factors; sutureless surgical procedures/adverse effects/instrumentation/methods; time factors; treatment outcome

**From:** Department of Cardiovascular Surgery, University of Health Sciences, Ahi Evren Thoracic and Cardiovascular Surgery Research and Education Hospital, 61040 Trabzon, Turkey

**Address for reprints:**  
Muhammet Onur Hanedan,  
MD, Ahi Evren GKDC Egitim  
ve Arastirma Hastanesi,  
Soguksu Mah. Vatan Cad.  
No:9, 61040 Trabzon, Turkey

**E-mail:**  
ohanedan@hotmail.com

© 2018 by the Texas Heart®  
Institute, Houston

In the treatment of severe aortic stenosis, replacement of native aortic valves (AVs) with biological or mechanical prostheses has been the gold standard.<sup>1</sup> Because people are living longer, the need for AV replacement (AVR) has grown<sup>2</sup>; in many, concomitant cardiac surgical procedures are also necessary.<sup>3</sup> The use of sutureless AVs has increased,<sup>4</sup> and extending their use in patients with concomitant mitral disease might be of substantial benefit.<sup>5</sup>

Transcatheter AVR (TAVR) has been used to treat isolated AV disease in high-risk patients who are not eligible for surgery involving cardiopulmonary bypass (CPB). Moreover, the durability of TAVR is uncertain; it is associated with paravalvular leak (PVL) and neurologic events, and it increases risks during pacemaker implantation.<sup>6</sup> In addition, percutaneous approaches typically do not enable treating concomitant cardiac conditions. In this study, we compared the outcomes of sutureless AVR with those of conventional bioprosthetic and mechanical AVR in elderly patients who underwent concomitant cardiac surgical procedures.

### Patients and Methods

We enrolled 70 elderly patients into this retrospective, nonrandomized study; all had been treated at our hospital from October 2009 through August 2016. We included 42 men and 28 women (mean age, 70.4 ± 10.3 yr; range, 34–93 yr). Inclusion criteria were severe symptomatic AV disease, New York Heart Association (NYHA) functional class II or worse, and planned surgical AVR with concomitant cardiac surgical procedures. The patients were divided into 2 groups: 38 underwent sutureless AVR (group 1), and 32 underwent conventional bioprosthetic or mechanical AVR (group 2). Written informed consent to participate was obtained from all patients except for those treated under emergency status. Our local ethics committee approved the study protocol.

Table I shows the preoperative data. The mean logistic EuroSCORE was  $8.63 \pm 1.86$  in group 1 and  $8.08 \pm 0.63$  in group 2 ( $P=0.093$ ). The groups were comparable except for worse NYHA functional status and more patients with diabetes mellitus in group 1.

In group 1, we implanted an Edwards INTUITY valve (Edwards Lifesciences Corporation) in 27 patients and a PERCEVAL™ S valve (SORIN, part of LivaNova PLC) in 11 patients. In group 2, we placed a SORIN SOPRANO™ valve (LivaNova) in 10 patients, a SORIN FREEDOM SOLO™ (LivaNova) in 9, a Trifecta™ (St. Jude Medical, Inc.) in 5, and a St. Jude Medical mechanical valve in 8. Follow-up evaluation included analysis of outpatient clinical data and postoperative echocardiograms.

### Operative Technique

The same surgeon operated on all the patients. After induction of general anesthesia, orotracheal intubation, and full sternotomy, all patients were placed on CPB. Myocardial protection was achieved via the antegrade administration of cold-blood cardioplegic solution on induction and was continued via antegrade or selective ostial doses of cold-blood cardioplegic solution every 20 min, in accordance with our hospital's protocol. A final warm-blood dose preceded release of the aortic cross-clamp. Transverse aortotomy was performed approximately 1 cm above the sinotubular junction for the PERCEVAL S valve and in standard fashion for the Edwards INTUITY valve. The native AV was excised and the annular calcifications were removed. Intraoperative transesophageal echocardiography (TEE) was used to evaluate the prosthesis.

The PERCEVAL S and Edwards INTUITY valves are approved for clinical use in Europe and Turkey, and we have used them often.<sup>7,8</sup>

### Statistical Analysis

Statistics were analyzed by using SPSS version 16.0 (SPSS Inc., an IBM company). Data were expressed as mean  $\pm$  SD for quantitative variables and as number and percentage for categorical variables. The groups were compared by means of the Student *t* test for continuous variables and the  $\chi^2$  or Fisher exact test for categorical variables. Cumulative survival curves were computed in accordance with the Kaplan-Meier method. The log-rank test was used to compare survival outcomes. Multivariate analysis was performed by using a binary logistic regression model to identify independent risk factors for 30-day death. Survival outcomes were further evaluated after multivariate Cox regression analysis. A *P* value  $<0.05$  was considered statistically significant.

### Results

Table II shows the operative and postoperative results. In group 1, we observed significantly shorter operative, CPB, and cross-clamp times. In-hospital mortality rates and lengths of intensive care unit stay were similar between the groups; in contrast, group 1 patients had significantly less need for drainage and red blood cell transfusions, and shorter hospital stays. The chief concomitant procedure was coronary artery bypass grafting (CABG), for 76.3% of patients in group 1 and 65.6% in group 2 (Table III).

**TABLE I.** Preoperative Demographic and Clinical Characteristics of the 70 Patients

| Variable                            | Group 1 (Sutureless AVR)<br>(n=38) | Group 2 (Conventional AVR)<br>(n=32) | P Value |
|-------------------------------------|------------------------------------|--------------------------------------|---------|
| Age (yr)                            | 71.2 $\pm$ 8.9                     | 69.5 $\pm$ 11.8                      | 0.507   |
| Male                                | 19 (50)                            | 23 (71.9)                            | 0.063   |
| NYHA functional class               | 2.7 $\pm$ 0.6                      | 2.2 $\pm$ 0.4                        | 0.001   |
| LV ejection fraction                | 0.56 $\pm$ 0.11                    | 0.55 $\pm$ 0.11                      | 0.802   |
| Body surface area (m <sup>2</sup> ) | 1.75 $\pm$ 0.15                    | 1.77 $\pm$ 0.27                      | 0.696   |
| Smoking                             | 16 (42.1)                          | 9 (28.1)                             | 0.224   |
| Diabetes mellitus                   | 11 (28.9)                          | 3 (9.4)                              | 0.039   |
| Carotid artery disease              | 4 (10.5)                           | 5 (15.6)                             | 0.722   |
| Peripheral vascular disease         | 3 (7.9)                            | 2 (6.3)                              | 0.999   |
| Renal failure                       | 1 (2.6)                            | 1 (3.1)                              | 0.999   |
| COPD                                | 8 (21.1)                           | 3 (9.4)                              | 0.181   |
| Logistic EuroSCORE                  | 8.63 $\pm$ 1.86                    | 8.08 $\pm$ 0.63                      | 0.093   |

AVR = aortic valve replacement; COPD = chronic obstructive pulmonary disease; LV = left ventricular; NYHA = New York Heart Association

Data are expressed as mean  $\pm$  SD or as number and percentage. *P*  $<0.05$  was considered statistically significant.

Table IV shows the patients' pre- and postoperative echocardiographic results. The mean postoperative aortic gradients were  $8.4 \pm 2.8$  mmHg in group 1 and  $12.2 \pm 5.2$  mmHg in group 2 ( $P=0.012$ ). Neither the postoperative nor the follow-up gradients differed between patients with the PERCEVAL and INTUITY valves.

Patients were monitored for  $789.1 \pm 634.3$  days. The mean durations were  $507.5 \pm 350.8$  days (range, 6–1,054 d) in group 1, and  $1,123.4 \pm 732.1$  days (range, 1–2,486 d) in group 2. We observed no difference in survival outcome ( $P=0.065$ ) (Fig. 1).

Our model revealed no independent risk factor that predicted 30-day death.

The only predictor of midterm death was CPB time (hazard ratio=1.05; 95% CI, 1.017–1.084;  $P=0.002$ ). For cross-clamp time, the hazard ratio was 0.963 (95% CI, 0.927–1.0;  $P=0.052$ ).

Because of substantial PVL in one patient, we performed early prosthesis explantation and implanted a different prosthesis 3 days later. We detected no moderate or severe PVL in any other patient.

## Discussion

Several types of sutureless AVs have been introduced into clinical practice. Sutureless AVR can be the first-

**TABLE II.** Comparison of Operative and Postoperative Results

| Variable                       | Group 1 (Sutureless AVR)<br>(n=38) | Group 2 (Conventional AVR)<br>(n=32) | P Value |
|--------------------------------|------------------------------------|--------------------------------------|---------|
| Operative time (min)           | 253 ± 76                           | 350 ± 85                             | 0.001   |
| Cross-clamp time (min)         | 78 ± 28                            | 122 ± 38                             | 0.001   |
| CPB time (min)                 | 119 ± 42                           | 166 ± 50                             | 0.001   |
| Ventilator dependence (hr)     | 9.4 ± 3.5                          | 11.6 ± 7.8                           | 0.134   |
| Intensive care unit stay (d)   | 4.2 ± 3.7                          | 4.9 ± 4.8                            | 0.462   |
| Drainage (mL)                  | 396 ± 153                          | 1,010 ± 1,208                        | 0.009   |
| Re-exploration for bleeding    | 2 (5.3)                            | 2 (6.3)                              | 0.999   |
| Red blood cell transfusion (U) | 2.2 ± 1.8                          | 3.4 ± 3                              | 0.037   |
| FFP transfusion (U)            | 2.2 ± 1.9                          | 2.9 ± 3.4                            | 0.262   |
| 30-day hospital death          | 2 (5.3)                            | 5 (15.6)                             | 0.234   |
| Hospital stay (d)              | 9.3 ± 5.1                          | 13.6 ± 6.6                           | 0.004   |

AVR = aortic valve replacement; CPB = cardiopulmonary bypass; FFP = fresh frozen plasma

Data are expressed as mean ± SD or as number and percentage.  $P < 0.05$  was considered statistically significant.

**TABLE III.** Comparison of Concomitant Procedures

| Variable                        | Group 1 (Sutureless AVR)<br>(n=38) | Group 2 (Conventional AVR)<br>(n=32) |
|---------------------------------|------------------------------------|--------------------------------------|
| CABG                            | 29 (76.3)                          | 21 (65.6)                            |
| CABG + ascending aortic surgery | 3 (7.9)                            | 1 (3.1)                              |
| CABG + mitral ring annuloplasty | 1 (2.6)                            | 2 (6.3)                              |
| CABG + mitral valve replacement | 1 (2.6)                            | 1 (3.1)                              |
| Ascending aortic surgery        | 3 (7.9)                            | 2 (6.3)                              |
| Mitral ring annuloplasty        | 0                                  | 2 (6.3)                              |
| Mitral valve replacement        | 1 (2.6)                            | 1 (3.1)                              |
| Tricuspid annuloplasty          | 0                                  | 1 (3.1)                              |
| Atrial septal defect repair     | 0                                  | 1 (3.1)                              |

AVR = aortic valve replacement; CABG = coronary artery bypass grafting


Data are presented as number and percentage.

**TABLE IV.** Comparison of Pre- and Postoperative Echocardiographic Findings

| Variable                       | Group 1 (Sutureless AVR)<br>(n=38) | Group 2 (Conventional AVR)<br>(n=32) | P Value |
|--------------------------------|------------------------------------|--------------------------------------|---------|
| <b>Preoperative</b>            |                                    |                                      |         |
| LV ejection fraction           | 0.56 ± 0.11                        | 0.55 ± 0.11                          | 0.802   |
| LV end-diastolic diameter (mm) | 49.8 ± 5.9                         | 50.4 ± 9                             | 0.744   |
| LV end-systolic diameter (mm)  | 32.3 ± 7.5                         | 33.6 ± 9                             | 0.514   |
| IVST (mm)                      | 12.9 ± 2.2                         | 13.7 ± 2.1                           | 0.135   |
| Posterior wall thickness (mm)  | 12.3 ± 1.8                         | 13.2 ± 1.7                           | 0.039   |
| Peak aortic gradient (mmHg)    | 62.4 ± 22                          | 72.5 ± 20                            | 0.059   |
| Mean aortic gradient (mmHg)    | 37.4 ± 13.9                        | 47.6 ± 12.7                          | 0.003   |
| <b>Postoperative</b>           |                                    |                                      |         |
| LV ejection fraction           | 0.55 ± 0.12                        | 0.53 ± 0.11                          | 0.584   |
| LV end-diastolic diameter (mm) | 49 ± 5.6                           | 50.6 ± 8.9                           | 0.428   |
| LV end-systolic diameter (mm)  | 32.1 ± 7.5                         | 34.6 ± 8.2                           | 0.256   |
| IVST (mm)                      | 12.7 ± 2.1                         | 13.0 ± 2                             | 0.617   |
| Posterior wall thickness (mm)  | 12.3 ± 2                           | 12.4 ± 1.6                           | 0.828   |
| Peak aortic gradient (mmHg)    | 19.9 ± 6.5                         | 23.6 ± 8.1                           | 0.087   |
| Mean aortic gradient (mmHg)    | 8.4 ± 2.8                          | 12.2 ± 5.2                           | 0.012   |

AVR = aortic valve replacement; IVST = interventricular septal thickness; LV = left ventricular

Data are expressed as mean ± SD. *P* <0.05 was considered statistically significant.



**Fig. 1** Kaplan-Meier survival curve shows similar survival outcomes for both aortic valve replacement (AVR) groups.

line treatment for isolated AVR in elderly patients who have severe comorbidities, delicate aortic wall conditions (such as calcified root, porcelain aorta, or those resulting from repeat procedures), the need for time-consuming concomitant operations, or small aortic roots. The benefits of sutureless-valve technology in-

clude easy and rapid implantability; easy repositioning; shorter cross-clamp and CPB times; complete removal of the stenotic native AV; favorable hemodynamic performance (a larger orifice area); the ability for concomitant procedures to be performed; lower rates of vascular complications, stroke, and PVL; and less need for permanent pacemakers.

Authors of published series<sup>9-14</sup> on isolated AVR in high-risk elderly patients reported operative mortality rates of 0 to 3% for sutureless AVR and 4% to 10% for conventional AVR. In comparison, the operative mortality rates in our cohort were 5.3% and 15.6%, respectively—higher, we speculate, because patients in both groups underwent complex concomitant procedures.

Lengthy aortic cross-clamp and total CPB times have been associated with poor clinical outcomes in AVR. In a retrospective analysis of 979 patients who had undergone surgical AVR,<sup>15</sup> cross-clamp time independently predicted severe cardiovascular morbidity (increased risk, 1.4% per 1-min increase). Consistent with an earlier report,<sup>16</sup> the shorter CPB and cross-clamp times in our group 1 patients resulted in less drainage, less need for red blood cell transfusion, and shorter hospital stays.

In both our groups, AVR brought substantial symptomatic improvement and reduced transvalvular pressure gradients. Before our patients' discharge from the hospital, echocardiograms showed lower aortic gradients in group 1, which is consistent with other reports.<sup>5,17,18</sup>

## Paravalvular Leak

Optimally, sutureless procedures permit full removal of the native AV and enable thorough annular decalcification, thereby lowering the risk of PVL. Nevertheless, PVL often influences the outcomes of sutureless AVR. Chief contributory factors are stenotic remnants of the native AV, residual annular calcification, intrinsic valve design, and operative variables such as incorrect sizing or positioning.<sup>11</sup> Preprocedural echocardiographic analysis is crucial to determine anatomic contraindications to sutureless AVR, such as aortic root dilation, an annular-to-sinotubular junction ratio >1:3, and an aortomitral curtain <5 mm thick in concomitant mitral valve replacement.

Intraoperative TEE detects moderate-to-severe PVL so that it can be corrected immediately. Severe postprocedural PVL has been correlated with poor patient outcomes.<sup>19,20</sup> In sutureless AVR, the incidence of PVL has ranged from 1.6% to 15.8%<sup>21,22</sup>—significantly lower than that after TAVR but still greater than that after conventional AVR. Substantial PVL occurred in only one of our patients.

## Order of Surgical Procedures

When multiple procedures are planned, we recommend performing mitral valve intervention and left circumflex coronary artery bypass first, to minimize cardiac retraction and the consequent distortion or inadequate positioning of a sutureless AV. When the PERCEVAL S valve is used in association with CABG, the surgeon should ensure enough aortic length for proximal anastomoses. In addition, both procedures should be performed during the same aortic cross-clamp period. Because of prosthesis design, we recommend using the Edwards INTUITY valve if ascending aortic replacement is planned.

**Bicuspid Aortic Valves.** In the Sievers surgical classification of bicuspid AVs,<sup>23</sup> type 0 has no raphe, type 1 has one raphe, and type 2 has 2 raphes. Types 1 and 2 usually feature leaflets of unequal size, and the larger leaflet typically has a central raphe (or ridge) consequent to the fusion of 2 adjacent leaflet commissures. We have used sutureless valves in cases of bicuspid AV but think that the Edwards INTUITY is better. An annular diameter <25 mm might yield good results in type 0.<sup>24</sup> We increase the number of guiding sutures according to the situation.

**The Gray Zone.** It is debated whether TAVR or surgical AVR is better for patients in the “gray zone” of AV disease. The ideal candidate for sutureless AVR is an elderly patient who needs multiple interventions (such as CABG, multiple-valve surgery, or reoperation) and has several comorbid conditions that affect the choice between surgical AVR and TAVR. Muneretto and colleagues<sup>25</sup> compared the results of TAVR, conventional surgical AVR, and sutureless AVR in patients who were

at intermediate-to-high risk. These authors suggested that, at 24 months, patients who underwent TAVR had more perioperative complications and less freedom from major adverse cardiac events and prosthesis dysfunction than did patients who underwent surgical or sutureless AVR. D’Onofrio and colleagues<sup>26</sup> compared early clinical and echocardiographic outcomes of patients who underwent surgical AVR, sutureless AVR with use of PERCEVAL valves, and transapical AVR. The authors reported lower 30-day mortality and postoperative aortic regurgitation rates in the surgical group than in the TAVR group, and no difference in mortality rates between the sutureless and TAVR groups.

## Study Limitations

The limitations of this study are its single-center nature, small sample size, and nonrandomized design. This study focused on early hemodynamic and midterm survival outcomes, so long-term follow-up data from randomized clinical trials will be needed to evaluate durability, clinical outcomes, and sequelae.

**Conclusion.** Although proposing final conclusions would be premature, our results show that sutureless AVR provides favorable results and can be the first option for elderly, high-risk patients who need AVR and concomitant cardiac surgical procedures.

## References

1. Eichstaedt HC, Easo J, Harle T, Dapunt OE. Early single-center experience in sutureless aortic valve implantation in 120 patients. *J Thorac Cardiovasc Surg* 2014;147(1):370-5.
2. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur J Cardiothorac Surg* 2012;42(4):S1-44.
3. Mataraci I, Hanedan MO, Sayar U, Yuruk MA, Ozer T, Arslan AK, Yucel M. Early outcomes of the sutureless aortic valves versus conventional stented bioprosthetic valves. *Turk Gogus Kalp Dama* 2016;24(2):240-7. Available at: [http://tgkdc.dergisi.org/pdf/pdf\\_TGKDC\\_2363.pdf](http://tgkdc.dergisi.org/pdf/pdf_TGKDC_2363.pdf).
4. Shrestha M, Folliguet TA, Pfeiffer S, Meuris B, Carrel T, Bechtel M, et al. Aortic valve replacement and concomitant procedure with the Perceval valve: results of European trials. *Ann Thorac Surg* 2014;98(4):1294-300.
5. Minh TH, Mazine A, Bouhout I, El-Hamamsy I, Carrier M, Bouchard D, Demers P. Expanding the indication for sutureless aortic valve replacement to patients with mitral disease. *J Thorac Cardiovasc Surg* 2014;148(4):1354-9.
6. Gersak B, Fischlein T, Folliguet TA, Meuris B, Teoh KH, Moten SC, et al. Sutureless, rapid deployment valves and stented bioprosthesis in aortic valve replacement: recommendations of an International Expert Consensus Panel. *Eur J Cardiothorac Surg* 2016;49(3):709-18.
7. Hanedan MO, Mataraci I, Yuruk MA, Ozer T, Sayar U, Arslan AK, et al. Early outcomes of sutureless aortic valves. *Korean J Thorac Cardiovasc Surg* 2016;49(3):165-70.

8. Ihsan Parlar A, Hanedan MO, Mataraci I, Yuruk MA, Sayar U, Arslan AK, Ozer T. Immediate outcomes of aortic valve replacement with sutureless versus stentless bioprosthesis. *J Heart Valve Dis* 2016;25(1):21-7.
9. Di Eusanio M, Fortuna D, De Palma R, Dell'Amore A, Lammara M, Contini GA, et al. Aortic valve replacement: results and predictors of mortality from a contemporary series of 2256 patients. *J Thorac Cardiovasc Surg* 2011;141(4):940-7.
10. Flameng W, Herregods MC, Hermans H, van der Mieren G, Vercalsteren M, Poortmans G, et al. Effect of sutureless implantation of the Perceval S aortic valve bioprosthesis on intraoperative and early postoperative outcomes. *J Thorac Cardiovasc Surg* 2011;142(6):1453-7.
11. Folliguet TA, Laborde F, Zannis K, Ghorayeb G, Haverich A, Shrestha M. Sutureless Perceval aortic valve replacement: results of two European centers. *Ann Thorac Surg* 2012;93(5):1483-8.
12. Santarpino G, Pfeiffer S, Schmidt J, Concistre G, Fischlein T. Sutureless aortic valve replacement: first-year single-center experience. *Ann Thorac Surg* 2012;94(2):504-9.
13. Shrestha M, Folliguet T, Meuris B, Dibie A, Bara C, Herregods MC, et al. Sutureless Perceval S aortic valve replacement: a multicenter, prospective pilot trial. *J Heart Valve Dis* 2009;18(6):698-702.
14. Breitenbach I, Wimmer-Greinecker G, Bockeria LA, Sadowski J, Schmitz C, Kapelak B, et al. Sutureless aortic valve replacement with the Trilogy Aortic Valve System: multicenter experience. *J Thorac Cardiovasc Surg* 2010;140(4):878-84.
15. Ranucci M, Frigiola A, Menicanti L, Castelvechio S, de Vincentiis C, Pistuddi V. Aortic cross-clamp time, new prostheses, and outcome in aortic valve replacement. *J Heart Valve Dis* 2012;21(6):732-9.
16. Pollari F, Santarpino G, Dell'Aquila AM, Gazdag L, Alnahas H, Vogt F, et al. Better short-term outcome by using sutureless valves: a propensity-matched score analysis. *Ann Thorac Surg* 2014;98(2):611-7.
17. Altintas G, Diken AI, Hanedan O, Yurdakok O, Ozyalcin S, Kucuker SA, Ozatik MA. The Sorin Freedom SOLO stentless tissue valve: early outcomes after aortic valve replacement. *Tex Heart Inst J* 2013;40(1):50-5.
18. Borger MA, Carson SM, Ivanov J, Rao V, Scully HE, Feindel CM, David TE. Stentless aortic valves are hemodynamically superior to stented valves during mid-term follow-up: a large retrospective study. *Ann Thorac Surg* 2005;80(6):2180-5.
19. Sponga S, Perron J, Dagenais F, Mohammadi S, Baillet R, Doyle D, et al. Impact of residual regurgitation after aortic valve replacement. *Eur J Cardiothorac Surg* 2012;42(3):486-92.
20. Genereux P, Head SJ, Hahn R, Daneault B, Kodali S, Williams MR, et al. Paravalvular leak after transcatheter aortic valve replacement: the new Achilles' heel? A comprehensive review of the literature. *J Am Coll Cardiol* 2013;61(11):1125-36.
21. Englberger L, Carrel TP, Doss M, Sadowski J, Bartus K, Eckstein FF, et al. Clinical performance of a sutureless aortic bioprosthesis: five-year results of the 3f Enable long-term follow-up study. *J Thorac Cardiovasc Surg* 2014;148(4):1681-7.
22. D'Onofrio A, Messina A, Lorusso R, Alfieri OR, Fusari M, Rubino P, et al. Sutureless aortic valve replacement as an alternative treatment for patients belonging to the "gray zone" between transcatheter aortic valve implantation and conventional surgery: a propensity-matched, multicenter analysis. *J Thorac Cardiovasc Surg* 2012;144(5):1010-6.
23. Sievers HH, Schmidtke C. A classification system for the bicuspid aortic valve from 304 surgical specimens. *J Thorac Cardiovasc Surg* 2007;133(5):1226-33.
24. Vola M, Guichard JB, Campisi S, Fuzellier JF, Gerbay A, Doguet F, et al. Sutureless aortic bioprosthesis valve implantation and bicuspid valve anatomy: an unsolved dilemma? *Heart Vessels* 2016;31(11):1783-9.
25. Muneretto C, Bisleri G, Moggi A, Di Bacco L, Tespili M, Repposini A, Rambaldini M. Treating the patients in the 'grey-zone' with aortic valve disease: a comparison among conventional surgery, sutureless valves and transcatheter aortic valve replacement. *Interact Cardiovasc Thorac Surg* 2015;20(1):90-5.
26. D'Onofrio A, Rizzoli G, Messina A, Alfieri O, Lorusso R, Salizzoni S, et al. Conventional surgery, sutureless valves, and transapical aortic valve replacement: what is the best option for patients with aortic valve stenosis? A multicenter, propensity-matched analysis. *J Thorac Cardiovasc Surg* 2013;146(5):1065-71.